Share Price:GBX

Day Change:

Trading suspended

Click for more information

AIM symbol: REDX
Issued Shares: 126,477,914
Market Cap: £40.95M

Quoted at 00:09:15 BST on 20 September 2017    Data is delayed by 15+ minutes    The London Stock Exchange is currently closed

Company Summary

Redx Pharma is an established drug discovery and development company, formed in late 2010. The Group is focused on the development of proprietary, small molecule therapeutics to address areas of high unmet medical need, principally in cancer and fibrosis. Redx Pharma's work has been endorsed by major partnerships with global pharmaceutical companies and the NHS.

Latest Regulatory News

Order for distribution to Unsecured Creditors 24 Aug 2017
The Joint Administrators' Proposals 10 Aug 2017
Distribution to Unsecured Creditors 24 Aug 2017   09:42
Directorate Change 14 Aug 2017   10:05
Publication of Joint Administrators' Proposals 10 Aug 2017   08:00
Disposal of BTK inhibitor drug development program 31 Jul 2017   07:00
MHRA approval of Clinical Trial Application 23 Jun 2017   14:38
Update on Suspension of Trading 22 Jun 2017   07:00

Share price data and investor tools provided by Brighter IR, subject to their Terms & Conditions

More Regulatory News

Latest Publication

poster preview image of 2017 ESMO: Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening

ESMO: Identification of RNF43 mutated gastric cancer with potential sensitivity to porcupine inhibitor RXC004,
15 September 2017

Latest Video

ProactiveInvestors, 17 May 2017

Redx Pharma “in a very good place with great assets”